Effect of valproate on the plasma concentrations of aripiprazole in bipolar patients

References

• Baumann P, Ulrich S, Eckermann G, Gerlach M, Kuss HJ, Laux G, et al. 2005. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 7:231–247.
   PubMedGoogle Scholar
• Castberg I, Spigset O. 2007. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 40:107–110.
   PubMed Web of Science ®Google Scholar
• Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. 2005. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 45:89–93.
   PubMed Web of Science ®Google Scholar
• De Fazio P, Girardi P, Maina G, Mauri MC, Mauri M, Monteleone P, et al. 2010. Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group. Clin Drug Investig 30:827–841.
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. 2004. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649–666.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E. 2009. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 27:1–15.
   Google Scholar
• Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM. 2000. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61:9–15.
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. 2013. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23: 236–241.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Consensus Group of the British Association for Psychopharmacology. 2009. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23:346–388.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. 2011. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 44:195–235.
   Web of Science ®Google Scholar
• Jaffe R. 2002. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, 2nd ed. Am J Psychiatry 159:331.
   Google Scholar
• Kanba S, Kawasaki H, Ishigooka J, Sakamoto K, Kinoshita T, Kuroki T. 2014. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). World J Biol Psychiatry 15:113–121.
   PubMed Web of Science ®Google Scholar
• Keck PE, Bowden CL, Meinhold JM, Gyulai L, Prihoda TJ, Baker JD, et al. 2005. Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. Int J Psychiatry in Clin Pract 9:271–277.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. 2008. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet 47:533–542.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Yoon J, Jerrell JM, Liauw SS. 2011. Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatr Dis Treat 7:319–323.
   PubMed Web of Science ®Google Scholar
• McKeage K. 2014. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. CNS Drugs 28:171–183.
   Google Scholar
• Monkul S, Akdede B. 2005. Aripiprazole: A new atypical antipsychotic drug. Klinik Psikofarmakoloji Bülteni;15:198–203.
   Google Scholar
• Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R. 2011. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 13:133–144.
   PubMed Web of Science ®Google Scholar
• Molden E, Lunde H, Lunder N, Refsum H. 2006. Pharmacokinetic variability of aripiprazole and the active metabolite dehyd roaripiprazole in psychiatric patients. Ther Drug Monit 28: 744–749.
   PubMed Web of Science ®Google Scholar
• Perucca E. 2002. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695–714.
   PubMed Web of Science ®Google Scholar
• Product Information. 2002. Abilify (Aripiprazole) tablets. Princeton, NJ: Bristol-Myers Squibb Company.
   Google Scholar
• Rado J, Janicak PG. 2010. Aripiprazole for late-life schizophrenia. Clinical Interv Aging 5:253–258.
   Web of Science ®Google Scholar
• Sayyaparaju KK, Grunze H, Fountoulakis KN. 2014. When to start aripiprazole therapy in patients with bipolar mania. Neuropsychiatr Dis Treat. 10:459–470.
   Web of Science ®Google Scholar
• Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, et al. 2006. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 190:373–382.
   Google Scholar
• Tadori Y, Forbes RA, McQuade RD, Kikuchi T. 2008. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 597:27–33.
   PubMed Web of Science ®Google Scholar
• Tang Ching-Shu, Yeh Chin-Bin, Huang Yu-Shu, Wang Liang-Jen, Chou Wen-Jiun, Chou Miao-Chun, Chen Chih-Ken et al. 2010. Long-term effectiveness of aripiprazole in adolescents and young adults with bipolar disorder: A naturalistic study. Int J Psychiatry Clin Pract 14:252–256.
   PubMed Web of Science ®Google Scholar
• Thase ME, Bowden CL, Nashat M, Eudicone JM, Marcus R, McQuade RD, et al. 2012. Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. Int J Psychiatry Clin Pract 16:121–131.
   PubMed Web of Science ®Google Scholar
• Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L. 2004. Antipsychotics in bipolar disorders. Encephale 30:417–424.
   Web of Science ®Google Scholar
• Vieta E, T'joen C, McQuade RD, Carson WH, Marcus RN, Sanchez R, et al. 2008. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: A placebo-controlled study. Am J Psychiatry 165:1316–1325.
   PubMed Web of Science ®Google Scholar
• Vieta E, Owen R, Baudelet C, McQuade R.D, Sanchez R, Marcus R.N. 2010. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 26:1485–1496.
   PubMed Web of Science ®Google Scholar
• Waade RB, Christensen H, Rudberg I, Refsum H, Hermann M. 2009. Influence of comedication on serum concentrations of aripi- prazole and dehydroaripiprazole. Ther Drug Monit 31: 233–238.
   PubMed Web of Science ®Google Scholar
• Woo YS, Bahk WM, Chung MY, Kim DH, Yoon BH, Lee JH, et al. 2011. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. Hum Psychopharmacol 26:543–553.
   PubMed Web of Science ®Google Scholar